MCL1 and acute myeloid leukemia: Several AML drugs have shown to synergise with VTX, both conventional agents like hypomethylating or chemotherapeutic agents (see [48] for a review) and new targeted therapies like FLT3 inhibitors [49] or MCL1 inhibitors [50].